The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
Antifungal Peptides as Therapeutic Agents
Open accessAbstract
Fungi have been used since ancient times in food and beverage-making processes and, more recently, have been harnessed for the production of antibiotics and in processes of relevance to the bioeconomy. Moreover, they are starting to gain attention as a key component of the human microbiome. However, fungi are also responsible for human infections. The incidence of community-acquired and nosocomial fungal infections has increased considerably in recent decades. Antibiotic resistance development, the increasing number of immunodeficiency- and/or immunosuppression-related diseases and limited therapeutic options available are triggering the search for novel alternatives. These new antifungals should be less toxic for the host, with targeted or broader antimicrobial spectra (for diseases of known and unknown etiology, respectively) and modes of actions that limit the potential for the emergence of resistance among pathogenic fungi. Given these criteria, antimicrobial peptides with antifungal properties, i.e., antifungal peptides (AFPs), have emerged as powerful candidates due to their efficacy and high selectivity. In this review, we provide an overview of the bioactivity and classification of AFPs (natural and synthetic) as well as their mode of action and advantages over current antifungal drugs. Additionally, natural, heterologous and synthetic production of AFPs with a view to greater levels of exploitation is discussed. Finally, we evaluate the current and potential applications of these peptides, along with the future challenges relating to antifungal treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
Mechanisms of Antimicrobial Peptide Action and Resistance
Yeaman, M. R., & Yount, N. Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.2 · Cited by 3,001
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“It is estimated that fungal diseases affect more than one billion people globally, of whom 150 million suffer from severe infections (Bongomin et al., 2017).”
BackgroundRecombinant protein expression in Escherichia coli: advances and challenges
Rosano, G. L., & Ceccarelli, E. A. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00172 · Cited by 2,556
APD3: the antimicrobial peptide database as a tool for research and education
Wang, G., Li, X., & Wang, Z. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1278 · Cited by 2,388
Designing antimicrobial peptides: form follows function
Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3591 · Cited by 2,035
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00194 · Cited by 1,927
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
The expanding scope of antimicrobial peptide structures and their modes of action
Nguyen, L. T., Haney, E. F., & Vogel, H. J. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.05.001 · Cited by 1,604
Cited by
Antimicrobial peptides as therapeutic agents: opportunities and challenges
Mahlapuu, M., Björn, C., & Ekblom, J. (2020) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2020.1796576 · Cited by 484
A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides
Browne, K., Chakraborty, S., Chen, R., Willcox, M. D., Black, D. S., Walsh, W. R., & Kumar, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197047 · Cited by 482
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Antimicrobial Peptides: An Update on Classifications and Databases
Bin Hafeez, A., Jiang, X., Bergen, P. J., & Zhu, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111691 · Cited by 341
Antimicrobial Peptides—Mechanisms of Action, Antimicrobial Effects and Clinical Applications
Talapko, J., Meštrović, T., Juzbašić, M., Tomas, M., Erić, S., Horvat Aleksijević, L., Bekić, S., Schwarz, D., Matić, S., Neuberg, M., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11101417 · Cited by 281
Metadata
- Authors
- Fernández de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E., & Cotter, P. D.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2020-03-17
- Volume
- 10
- Pages
- 105-105
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W3010686554
- Cited by
- 264
- References
- 198
- FWCI
- 19.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifungal Peptides as Therapeutic Agents. https://app.cochat.ai/papers/10.3389/fcimb.2020.00105
- The paper
- Fernández de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E., & Cotter, P. D. (2020). Antifungal Peptides as Therapeutic Agents. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2020.00105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
